Skip to Main Content

Agenda

Thursday, March 21, 2019

7:00 – 8:00 AM


Breakfast, Exhibits, and General Poster Session (Exhibition Hall)


8:00 – 8:10 AM


Welcome and Opening Remarks

Robert W. Carlson, MD
Chief Executive Officer
National Comprehensive Cancer Network

8:10 – 9:25 AM


Keynote Session: Patient Experience with Innovative Therapies 

Moderator: Frederick L. Locke, MD, Moffitt Cancer Center
Panelists: Jeffrey Backer, MD, FACEP, Emergency Physician; ​​Cancer Survivor
Alix Beaupierre, BSN, RN, OCN, Moffitt Cancer Center


9:25  – 9:40 AM

Break, Exhibits, and General Poster Session (Exhibition Hall)


9:40  – 10:55 AM

NCCN Roundtable Discussion: Emerging Issues in Oncology – 
Ensuring Access to, and Delivery of, Innovative Therapies and Patient Centered Care in Oncology 

 Moderator: Clifford Goodman, PhD, Senior Vice President, The Lewin Group

Panelists: Stefanie Joho, Survivor, Health Advocate, and Consultant;
Frederick L. Locke, MD, Moffitt Cancer Center; Jennifer Malin, MD, PhD, UnitedHealth Group;
John W. Sweetenham, MD, Huntsman Cancer Institute at the University of Utah;
Lalan S. Wilfong, MD, Texas Oncology

This non-accredited roundtable will provide an opportunity for a varied group of stakeholders including
providers, payers, patient advocates, industry, and government to discuss delivering and receiving
cancer therapies within patient centered models of care.

This session is supported separately from all other sessions on this agenda. Supported by Abbvie; Astellas; AstraZeneca; Celgene Corporation; Eisai Inc.; Foundation Medicine; Gilead Sciences Inc; Halozyme; Janssen; Karyopharm Therapeutics Inc.; Loxo Oncology; Novartis; Pharmacyclics, an AbbVie Company; and Sanofi-Genzyme. Sponsored by Bristol-Myers Squibb.

10:55  – 11:25 AM

Break, Exhibits, and General Poster Session (Exhibition Hall)


11:25 AM – 12:25 PM


NCCN Guidelines® Updates: New Immunotherapy Strategies for
Improving Outcomes in Non-Small Cell Lung Cancer

Marianne Davies, DNP, MSN, ACNP-BC, AOCNP
Yale Cancer Center/Smilow Cancer Hospital

Matthew A. Gubens, MD, MS
UCSF Helen Diller Family Comprehensive Cancer Center


12:25 – 1:40 PM


Lunch, Exhibits, and General Poster Session (Exhibition Hall)


Lunch Symposium§ 12:35 – 1:35 PM

Collaborative Strategies to Ensure Optimal Application of the
Latest Treatment Approaches in Hepatocellular Carcinoma
 


1:40 – 2:55 PM

NCCN Guidelines® Updates: Breast Cancer

Treatment of HR-Positive, HER-Negative Early Stage Breast Cancer

Melinda L. Telli, MD
Stanford Cancer Institute

Multigene Testing in Breast Cancer

John H. Ward, MD
Huntsman Cancer Institute at the University of Utah

Treatment of HR-Positive, HER-Negative Advanced Breast Cancer

William J. Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University 



2:55 – 3:25 PM


Break, Exhibits, and General Poster Session (Exhibition Hall)


3:25 – 4:10 PM


NCCN Guidelines® Updates: Treatment of Pancreatic Cancer

Margaret A. Tempero, MD
UCSF Helen Diller Family Comprehensive Cancer Center


4:15 – 5:00 PM


NCCN Guidelines® Updates: Management of Metastatic Kidney Cancer

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center


5:00 – 5:30 PM


Free Time


5:30 – 8:00 PM


Welcome Reception: 5:30 – 7:30 PM

(Exhibition Hall)

 
Kids' Fun Ni
ght! 5:30 – 8:00 PM


 

 

Friday, March 22, 2019

7:00 – 8:00 AM


Breakfast, Exhibits, and General Poster Session (Exhibition Hall)


8:00 – 8:45 AM


Improving Care Coordination to Optimize Health Outcomes in Cancer Survivors

Carlin Callaway, DNP, RN
University of Colorado Cancer Center

Linda Overholser, MD, MPH
University of Colorado Cancer Center


8:50 – 9:35 AM

 

Managing Pain in Patients and Survivors: Challenges within the U.S. Opioid Crisis

Judith A. Paice, PhD, RN
Robert H. Lurie Comprehensive Cancer Center of Northwestern University


9:40 – 10:25 AM


NCCN Guidelines® Updates: Management of Prostate Cancer

Emmanuel S. Antonarakis, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

James L. Mohler, MD
Roswell Park Comprehensive Cancer Center

10:25 – 10:50 AM

Break, Exhibits, and General Poster Session (Exhibition Hall) 

10:50 – 11:35 AM



Management of Central Nervous System Cancers

Clinical Practice Decisions in the Treatment of Meningiomas

Thomas Kaley, MD
Memorial Sloan Kettering Cancer Center

Evolving Treatment of Brain Metastases

Louis B. Nabors, MD
University of Alabama at Birmingham Comprehensive Cancer Center


11:40 – 12:25 PM

NCCN Guidelines® Updates:
Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia

Neil P. Shah, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center


12:25 – 1:40 PM

 

Lunch, Exhibits, and General Poster Session (Exhibition Hall)


Lunch Symposium§ 12:35 – 1:35 PM

PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing 
 

1:40 – 2:25 PM


 NCCN Guidelines® Updates: Management of Metastatic Colorectal Cancer

Wells A. Messersmith, MD
University of Colorado Cancer Center

 
 2:30 – 3:00 PM

  Screening for Distress in Cancer: Implementing the Standard of Care

Michelle B. Riba, MD, MS
University of Michigan Rogel Cancer Center


3:00 – 3:25 PM


Break, Exhibits, and General Poster Session (Exhibition Hall)


3:25 – 4:40 PM


Challenges with the 8th Edition of the AJCC Staging Manual

Staging of Breast Cancer


Aysegul A. Sahin, MD
The University of Texas MD Anderson Cancer Center

Staging of Testicular Cancer: Germ Cell Tumors

Timothy D. Gilligan, MD, MS
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center and
Cleveland Clinic Taussig Cancer Institute


Staging of Head and Neck Cancers: Oropharyngeal Cancer

Jimmy J. Caudell, MD, PhD
Moffitt Cancer Center


4:45 – 5:15 PM


New Biosimilar Approvals for Myeloid Growth Factors and Anemia

Gary H. Lyman, MD, MPH
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance




 Saturday, March 23, 2019

7:00 – 8:00 AM


Breakfast & Oral Poster Presentations


8:00 – 8:45 AM


Invited Presentation: NCCN Harmonized Guidelines™ for Sub-Saharan Africa

Abubakar M. Bello, MD
National Hospital Abuja


8:50 – 9:35 AM


NCCN Guidelines® Updates: Management of Muscle-Invasive Bladder Cancer

Thomas W. Flaig, MD
University of Colorado Cancer Center


9:40 – 10:25 AM


Novel Treatment Options for Neuroendocrine Tumors

Jonathan R. Strosberg, MD
Moffitt Cancer Center


10:25 – 10:40 AM


Break (Gatlin Ballroom Foyer)

 

10:40 – 11:25 AM


New Therapies for Ovarian Cancer

David M. O'Malley, MD
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute


11:30 AM – 12:15 PM


Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma

Anthony J. Olszanski, MD, RPh
Fox Chase Cancer Center 


12:15 – 1:00 PM


Lunch (Gatlin Ballroom Foyer)


1:00 – 1:45 PM


Navigating the Transition to End of Life Care in Patients with Cancer

Toby C. Campbell, MD, MSCI
University of Wisconsin Carbone Cancer Center


1:50 – 2:35 PM


Developments in Systemic Therapy for Soft-Tissue and Bone Sarcomas

Suzanne George, MD
Dana-Farber/Brigham and Women's Cancer Center


2:40 – 3:25 PM


Biomarker Testing for Immunotherapy

Jarushka Naidoo, MB BCh
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins


3:25 – 3:30 PM


Closing Remarks

Gary J. Weyhmuller, MBA, SPHR
Executive Vice President/Chief Operating Officer
National Comprehensive Cancer Network

 

 

§ These sessions are open to all health care providers attending the conference; pre-registration is not required. CME/CNE/CPE available. These symposia are accredited and supported separately from all other educational sessions on this agenda. Seating is limited and on a first-come, first-seated basis. Learn more about the satellite symposia here.

Agenda is subject to change. Speakers will be added once confirmed.

Top